HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer

We have shown that WT-161, a histone deacetylase 6 (HDAC6) inhibitor, shows remarkable anti-tumor activity in multiple myeloma (MM) in preclinical models. However, its activity in other type of cancers has not yet been shown. In this study, we further evaluated the biologic sequelae of WT161 in brea...

Descripción completa

Detalles Bibliográficos
Autores principales: Hideshima, Teru, Mazitschek, Ralph, Qi, Jun, Mimura, Naoya, Tseng, Jen-Chieh, Kung, Andrew L., Bradner, James E., Anderson, Kenneth C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655183/
https://www.ncbi.nlm.nih.gov/pubmed/29113288
http://dx.doi.org/10.18632/oncotarget.19019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655183/
https://www.ncbi.nlm.nih.gov/pubmed/29113288
http://dx.doi.org/10.18632/oncotarget.19019

Ejemplares similares